Exact Sciences' Cologuard sails through FDA panel
This article was originally published in Clinica
Executive Summary
Just a day after rival Epigenomics received a mixed verdict for its blood test Epi proColon, Exact Sciences’ stool-based colorectal cancer test Cologuard got a unanimous thumbs up from the US FDA advisory panel, boosting its chances of eventual approval.